Printer Friendly

Teva launches generic version of Letairis tablets in US.

Global Banking News-May 2, 2019-Teva launches generic version of Letairis tablets in US

(C)2019 ENPublishing - http://www.enpublishing.co.uk

Teva Pharmaceutical Industries Ltd (Teva) (TASE:TEVA) (NYSE:TEVA) announced on Wednesday the launch of a generic version of Letairis (ambrisentan) Tablets, 5 mg and 10 mg, in the US.

Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalisation for worsening PAH, as well as to improve exercise ability.

For all female patients, ambrisentan tablets are only available through a restricted programme called the Ambrisentan Risk Evaluation & Mitigation Strategy (REMS) due to the risk of foetal harm.

According to Teva, the launch of ambrisentan tablets in the US is an important addition to its growing generic portfolio of nearly 60 cardiovascular medicines.

With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Currently, one in eight generic prescriptions dispensed in the US is filled with a Teva generic product.

Teva Pharmaceutical Industries specialises in generic and specialty medicines.

((Distributed via M2 Communications - http://www.m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Global Banking News (GBN)
Date:May 2, 2019
Words:224
Previous Article:Rite Aid now compliant wit NYSE minimum average share price listing standard.
Next Article:Xvivo Perfusion announces approval of heart preservation fluid patents in US and Europe.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters